| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
Burrows Scott L is a Chief Financial Officer at SYRE, with reported holdings spanning 2 companies. Recent filings cover 0 purchases and 36 sales. Those positions are worth an estimated $8.5M at current prices.
Our model assigns Burrows Scott L a strong insider score of 72/100, based on 12 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +22.8%.
Burrows Scott L's largest disclosed position is in SYRE as Chief Financial Officer, worth about $7.6M. The recent filings there lean toward selling, a net 147,691 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 25,000 | $90.47 | $2,261,830.98 | -23.9% | - | - | |
| Sep 2, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 25,732 | $88.75 | $2,283,820.92 | -24.4% | - | - | |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $95.57 | $716,771.00 | -7.1% | - | - | |
| Jul 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $87.74 | $658,039.50 | -7.1% | - | - | |
| Jun 25, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 15,000 | $87.13 | $1,307,000.00 | -13.3% | - | - | |
| Jun 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $71.06 | $532,936.98 | -7.1% | - | - | |
| May 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 12,500 | $71.37 | $892,125.00 | -11.3% | +46.2% | - | |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $49.34 | $370,076.00 | -7.1% | +81.6% | - | |
| Mar 3, 2026 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 2,500 | $40.65 | $101,620.00 | -2.5% | +83.6% | - | |
| Sep 2, 2025 | SYRE Spyre Therapeutics, Inc. | Chief Financial Officer | Sell | 18,428 | $16.26 | $299,639.28 | -15.8% | +72.3% | - |